BIG News on Avian Flu GNBT will huge soon Government spending $7.1 billion on avian flu related costs
Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that senior representatives of the Company, together with executives of Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, presented a proposal today to interested senior senators to seek support for the accelerated development of its novel vaccine for H5N1 avian influenza.
The Company believes that the novel vaccine being developed at Antigen Express will be a valuable asset in combating avian influenza. The vaccine being developed is based on a proprietary platform technology whereby protein fragments (epitopes) from a novel antigen are identified and modified to enhance T helper cell stimulation. Activation of T helper cells has been shown to be essential in establishing an acquired immune response and in immunological memory. These features are particularly important in mounting an effective response to the potentially pandemic H5 strain of avian influenza.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.